Summit Therapeutics (SMMT) Earnings Date & Reports

Key Takeaways

• Summit Therapeutics is expected to report third quarter 2026 results around November 11, 2026, after the market close, covering the period ended September 30, 2026.
• Consensus estimates point to a generally accepted accounting principles (GAAP) loss per share of roughly $0.28 to $0.29, with revenue expected to remain minimal as the company is still pre-commercial.
• The report lands just days before the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026, for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC).
• Investors will focus on the cash position, research and development (R&D) spending trends, and updates across the company's three ongoing Phase III clinical trials.
• For more detail on Summit's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Explore Trending AI Robots to see how AI-driven trading tools are scanning the market for emerging opportunities.

Earnings Context and Why It Matters

Summit Therapeutics Inc. (SMMT) is a clinical-stage biopharmaceutical company that has become a closely watched name in oncology because of ivonescimab (SMT112), a bispecific antibody designed to target both PD-1 and VEGF. The company currently generates essentially no product revenue, so quarterly results are driven primarily by spending on drug development rather than sales. That makes this report significant for a different reason than a typical earnings release: it arrives only days before a potential first approval decision from the FDA. Investors will be parsing the financial update for signs of how well-funded Summit is to support a commercial launch and its expanding late-stage trial program.

Earnings Expectations

Because Summit is pre-revenue, the headline numbers are expected to show a net loss. Wall Street consensus points to a GAAP loss per share in the range of roughly $0.28 to $0.29 for the third quarter of 2026, though individual estimates vary. Revenue forecasts are negligible, generally under $0.1 million, reflecting the fact that the company has not yet begun selling a product.

In the second quarter of 2026, Summit reported a wider-than-expected GAAP loss as research and development costs climbed roughly 24% quarter over quarter to about $151.8 million in operating expenses, driven by three active Phase III trials and higher stock-based compensation. The company ended that period with approximately $690.7 million in cash, cash equivalents, and short-term investments, and it has since filed a new $380 million at-the-market (ATM) equity facility for additional financial flexibility. For the third quarter, investors will be watching whether expense growth continued and how much cash the company has on hand heading into a potential launch.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Summit Therapeutics alongside broader biotech momentum, the screener offers a structured way to surface candidates that match specific criteria.

Market Reaction and Investor Sentiment

Sentiment heading into this earnings event is shaped less by the financial figures and more by the regulatory decision that follows closely behind. Summit shares have traded in a wide range over the past year, and the stock carries a notably high short interest, a sign that a meaningful portion of the market is positioned against the company. After the second quarter report, which featured a wider-than-expected loss, the shares declined in after-hours trading, underscoring how sensitive the stock can be to spending trends and cash burn.

Key risk factors ahead of the release include the pace of expense growth, any dilution from the ATM facility, and uncertainty around the upcoming FDA decision. Because the PDUFA date falls just after the report, the market may treat the earnings call as a preview of management's confidence about commercialization plans.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the FDA's PDUFA goal action date of November 14, 2026, for ivonescimab in EGFR-mutated NSCLC. An approval would mark Summit's transition from a clinical-stage company to a commercial one and would refocus the narrative from spending toward launch execution.

Beyond that decision, investors should monitor the company's Phase III program. Top-line progression-free survival data from the HARMONi-3 squamous cohort is expected in the second half of 2026, with an interim overall survival analysis anticipated in the first half of 2027. Additional collaboration data is expected around mid-2027.

On the financial side, watch the cash runway and how the company manages rising R&D and selling, general, and administrative costs ahead of a potential launch. The newly filed ATM facility provides flexibility but also introduces the possibility of shareholder dilution. As always, this analysis does not constitute a price forecast or investment recommendation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations